3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Burkitt Lymphoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Down Syndrome
1
Interventions
Cyclophosphamide
11
Rituximab
10
Prednisone
8
Lenalidomide
8
Vincristine
7
Doxorubicin
7
Bendamustine Hydrochloride
6
obinutuzumab
5
Magnetic Resonance Spectroscopy
4
fludarabine
3
Whole-Body Irradiation
3
Specimen Handling
3
R-CHOP protocol
3
Cyclosporine
3
Biopsy
3
zanubrutinib
2
fludarabine phosphate
2
Radiotherapy
2
Prednisolone
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Mycophenolic Acid
2
Melphalan
2
Gemcitabine
2
Etoposide
2
Cytarabine
2
venetoclax
1
umbralisib
1
treosulfan
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
Methylprednisolone
×
30 days
×
Clear all
NCT06091254
2026-05-19
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3
Recruiting
822 enrolled